89bio, Inc. - Common Stock (ETNB)

The company is now focusing on MASH, a form of fatty liver disease common in people with obesity and type 2 diabetes.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

ETNB stock results show that 89bio beat analyst estimates for earnings per share the second quarter of 2024.

U.S. stock futures advanced on Thursday following Wednesday's mixed moves. Futures of major benchmark indices were higher.

U.S. stock futures trading higher, stocks to watch: Darden, Bullish, Factset. 89bio acquired by Roche. FedEx Q1 earnings expected.

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's have a look at the gap up and gap down stocks in today's session.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

The companies are both working on treatments for a liver disease known as MASH.

After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.

Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease.